Research professor at the National Biotechnology Centre (CNB-CSIC) and at the CIBERER-ISCIII
The US company Colossal Biosciences claims to have successfully incubated a bird in an artificial egg system until it hatched. In a press release, the company states that this technology allows a bird embryo to develop fully outside the shell of a biological egg, and could be used to bring back extinct bird species such as the giant moa from New Zealand’s South Island.
A team from the United States analyzed 611 samples from 341 model mouse strains stored at the Mutant Mouse Resource and Research Centers (MMRRC), a research resource network supported by the National Institutes of Health (NIH). By comparing the identity of each strain with its actual genetic profile, they found that approximately half of the samples showed discrepancies. Although the expected engineered mutation was generally present and many inconsistencies were relatively minor, some had the potential to compromise the validity and reproducibility of the experiments by introducing hidden genetic variables that could alter biological outcomes. The findings are published in Science.
Craig Venter, the American biologist and entrepreneur who founded Celera Genomics to launch his own Human Genome Project in 1999 outside the public consortium, died Wednesday in San Diego at the age of 79, according to a statement from the J. Craig Venter Institute, which he led. Among other achievements, Venter completed the first full sequencing of a living organism’s genetic material and announced that he had succeeded in creating synthetic life.
Repeated cloning cannot be sustained indefinitely in mammals, according to the findings of a twenty-year study on mice conducted in Japan. Serial cloning of mice led to an accumulation of lethal DNA mutations that affected birth rates from the 27th generation onwards, with the 58th generation being the last, according to the article published in Nature Communications, showing that sexual reproduction is necessary to prevent large-scale genetic mutations.
AlphaGenome is a deep learning model developed by Google DeepMind capable of predicting the function of DNA sequences up to one million base pairs long. An evaluation of the tool shows that it matches or improves upon the predictive ability of existing models in 25 of the 26 tests performed. According to the authors, who are part of Google DeepMind itself, AlphaGenome can help scientists "better understand genome function, the biology of diseases, and ultimately drive new biological discoveries and the development of new treatments." The results are published in Nature.
Two studies published today in the journal Nature significantly expand the catalogue of known human genetic variations. The resulting data constitute what may be the most complete view of the human genome to date.
In 2015, the United Kingdom became the first country to pass legislation allowing the use of mitochondrial donation technology, pronuclear transfer. The technique is designed to limit, through in vitro fertilization, the transmission of mitochondrial DNA diseases in babies born to women who are at high risk, and for which there is no cure. Two studies published in the New England Journal of Medicine (NEJM) describe the results of the first treatments performed to date, from which eight babies have been born by mitochondrial donation, with reduced risk of disease.
A team from the Netherlands has successfully edited pathogenic mutations in mitochondrial DNA in human cells, changes in DNA that cause disease, according to research published in PLoS Biology. The authors used a genetic tool known as a base editor. Until now, techniques derived from CRISPR have made it possible to correct mutations in nuclear DNA, and new techniques are being developed that allow mitochondrial DNA to be edited.
A team from the Children's Hospital of Philadelphia and Penn Medicine (United States) has successfully treated a baby diagnosed with a rare genetic disorder using personalised CRISPR gene editing therapy. The baby, known only by the initials KJ, was born with a rare metabolic disease known as severe carbamoyl phosphate synthetase 1 (CPS1) deficiency. After spending the first months of his life in hospital on a very restrictive diet, KJ received the first dose of his tailored therapy in February 2025, between six and seven months of age. The treatment, which is being used for the first time for this type of disorder, was administered safely, and the baby is now growing well and improving. The case is detailed in a study published by The New England Journal of Medicine (NEJM).
Colossal Biosciences has announced the creation of genetically modified mice with characteristics reminiscent of the fur of extinct mammoths, such as fur colour, texture and thickness. The non-peer-reviewed results were shared today in the BioRXiv prepublication repository.